3rd How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
Chairs: Caron Jacobson, Ulrich Jäger, Marie José Kersten

3rd How I Manage
CAR-T Therapies and Bispecific Antibodies for my Patients
Information
ABOUT THE CONFERENCE:
The programme of this ESH conference aims to provide an overview of the benefits and risks of currently available therapies for acute lymphoblastic leukaemia, lymphoma and multiple myeloma. Special focus will be placed on the advantages and disadvantages of bispecific antibodies vs. cellular therapies (including T cells, NK cells and transplant strategies). Future perspectives regarding applications in other haematological malignancies and in solid tumours will also be discussed.
The format of the meeting is based on the analysis and discussion of clinical case studies. It will adopt a problem-solving approach, addressing practical considerations and guidelines. Emphasis will be placed on open discussion, including a maximum level of interaction between faculty and registered participants.
In addition to the scientific and medical issues addressed during the conference, the questions of affordability and access to these novel expensive treatments will be tackled.
This educational conference has been approved for 17 CME-CPD credit points by the European Board for Accreditation in Haematology (EBAH)!
SCIENTIFIC TOPICS:
• Non-hodgkin lymphoma• Multiple myeloma
• Novel indications of CAR T-cell therapy
• CAR-T vs bispecific antibody in multiple myeloma
• Access to CAR-T and bispecific across the globe
• Mechanism of action and resistance to bispecifics
• Predictors of response and toxicity of CAR and bispecific
• Access issues in CAR T-cell treatment
• 1st line high-risk large B-cell lymphoma
• Real world data for CAR-T and bispecific
• Next Generation of CAR T-cell and bispecific antibody therapy
• Outsmarting the Escape Artist: resistance to CART immunotherapy
Programme
Read the final programme!





